Project Grant K99CA318464
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $128K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jacksonville, FL 32224, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville $599,699 on July 14, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop chimeric antigen receptor T-cell and tumor-infiltrating lymphocyte immunotherapies targeting glioblastoma. The research applies a "double-hit" strategy combining two adoptive T-cell therapies administered via Ommaya reservoir to bypass the...
- The National Cancer Institute awarded $498,582 to Mayo Clinic Jacksonville on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396, R01 Project Grant PA-25-301) to investigate acetylation as a post-translational mechanism that modulates T cell receptor signaling and enhances cancer immunotherapy efficacy. The research addresses suboptimal TCR signaling as a major immune resistance mechanism in cancer immunotherapy. The funded work establishes three primary aims: defining the role...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Institutes of Health National Cancer Institute awarded $687,314 to Mayo Clinic Jacksonville on July 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate senescence and resistance mechanisms in glioblastoma and to develop combination therapeutic strategies that overcome drug resistance. The funded research examines how glioblastomas develop resistance to mitotic kinase and kinesin inhibitors (ispinesib, alisertib, volasertib, and etoposide) through...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $163,320 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support radiation oncology leadership and clinical trial integration activities through August 30, 2031. The award funds the principal investigator's national and institutional leadership roles integrating radiation therapy within the National Clinical Trials Network (NCTN) and Mayo Clinic Comprehensive Cancer Center. Deliverables include...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $620,671 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a bioresorbable implant for local delivery of chemotherapy to aggressive meningiomas. The project addresses treatment limitations in meningioma management. Meningiomas are the most common adult central nervous system tumors, with over 36,000 diagnosed annually in the United States. Current treatment—maximal safe surgical resection...
- The National Cancer Institute awarded Mayo Clinic $565,423 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate individualized DNA junction-based liquid biopsies for monitoring glioblastoma and high-grade gliomas during and after treatment. The research addresses a clinical gap in glioma surveillance. Current magnetic resonance imaging monitoring using RANO 2.0 criteria lacks sensitivity and specificity for detecting early disease...
- The National Institutes of Health National Cancer Institute awarded Mayo Clinic $651,290 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing 93.395) to investigate the regulation of anti-tumor immunity by B7-H3, a protein overexpressed on many tumor types that suppresses immune responses. The research will identify the immune inhibitory receptors through which B7-H3 exerts its immunomodulatory effects during tumor responses, with particular focus on...
- The National Institutes of Health National Cancer Institute awarded H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. $589,581 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize gamma/delta CAR-T-cell therapy for bone metastatic castration-resistant prostate cancer. The award funds research to advance a novel immunotherapy combining autologous chimeric antigen receptor T-cell infusions with zoledronate treatment in metastatic...
- The National Cancer Institute awarded Mayo Clinic Arizona $237,660 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research elucidating the functional role of KLRG1-expressing CD4+ T conventional helper cells in the tumor microenvironment and developing a novel immunotherapy to selectively deplete KLRG1-expressing CD4+ T cells. The research investigates how KLRG1+ tumor-infiltrating T cells modify the tumor microenvironment and contribute to immune...